New One-Shot CAR-T therapy enters human testing for aggressive lymphoma
NCT ID NCT07456371
Summary
This is an early-stage study testing a new type of CAR-T cell therapy called PIC1 for adults with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to standard treatments. The main goal is to check if the treatment is safe and to see if it can help control the cancer. Participants will receive a single infusion of PIC1 and then be closely monitored for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.